Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
Status:
Terminated
Trial end date:
2008-09-30
Target enrollment:
Participant gender:
Summary
The main objectives of this proposal are as follows:
To assess the dynamic uptake and washout of 123-I MNI-330, a potential imaging biomarker for
β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in
similarly aged Alzheimer's (AD) subjects and healthy controls
To perform blood metabolite characterization of 123-I MNI-330 in healthy and AD subjects to
determine the metabolic fate and nature of metabolites in assessment of 123-I MNI-330 as a
single photon computed tomography (SPECT) brain imaging agent
Evaluate the test/retest reproducibility of 123-I MNI-330 and SPECT in AD subjects and
healthy controls